Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.5 EUR | -1.57% |
|
-1.19% | -58.88% |
05-22 | Transcript : Marinomed Biotech AG, Q1 2024 Earnings Call, May 22, 2024 | |
05-21 | Marinomed Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- The company has a low valuation given the cash flows generated by its activity.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The firm trades with high earnings multiples: 40.97 times its 2024 earnings per share.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-58.88% | 20.94M | - | ||
+2.75% | 94.22B | A- | ||
-3.42% | 37.76B | A- | ||
-13.75% | 32.5B | B- | ||
+73.19% | 27.75B | A | ||
-11.88% | 16.13B | C | ||
+0.49% | 14.19B | B- | ||
-12.95% | 11.42B | D+ | ||
+190.36% | 11.06B | D | ||
-54.07% | 9.09B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MARI Stock
- 93Z Stock
- Ratings Marinomed Biotech AG